BioMarin Pharmaceutical Inc.
Description
BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
About
CEO
Mr. Alexander Hardy
Employees
3,401
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
770 Lindaro Street, San Rafael, CA 94901, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 27, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| Apr 22, 2025 | — | — | — | — |
| Feb 20, 2025 | 0.54 | — | — | — |
| Oct 30, 2024 | 0.52 | 0.55 | 0.03 | 5.77% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 11 | — | 21 |
| Average estimate | — | 0.91 | — | 4.16 |
| Low estimate | — | 0.71 | — | 3.58 |
| High estimate | — | 1.06 | — | 4.87 |
| Last year EPS | — | 0.71 | — | 3.29 |
[stock_revenue_estimate]
Growth estimates
Current qtr
50.340%
Next qtr. (Mar 2025)
28.300%
Current year
58.150%
Next year (Dec 2025)
26.400%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 2.42B | 2.10B | 1.85B | 1.86B | 1.70B |
| Cost of revenue | 514.85M | 483.67M | 470.52M | 524.27M | 359.47M |
| Gross profit | 1.90B | 1.61B | 1.38B | 1.34B | 1.34B |
| Operating expense | |||||
| Research & development | 746.77M | 649.61M | 628.79M | 628.12M | 715.01M |
| Selling general and admin | 937.30M | 854.00M | 759.40M | 737.70M | 680.90M |
| Other operating expenses | — | — | — | — | — |
| Operating income | 158.10M | 45.96M | -74.33M | -91.83M | -104.83M |
| Non operating interest income | |||||
| Income | 58.34M | 18.03M | 10.48M | 16.61M | 22.75M |
| Expense | 16.74M | 15.38M | 14.74M | 27.48M | 21.43M |
| Other income expense | -10.54M | 101.55M | 3.85M | 55.46M | 10.76M |
| Pretax income | 188.56M | 149.58M | -75.35M | -49.00M | -94.81M |
| Tax provision | 20.92M | 8.02M | -11.27M | -903.03M | -70.96M |
| Net income | 167.65M | 141.56M | -64.08M | 854.03M | -23.85M |
| Basic EPS | 0.89 | 0.76 | -0.35 | 4.75 | -0.13 |
| Diluted EPS | 0.87 | 0.75 | -0.35 | 4.53 | -0.13 |
| Basic average shares | 187.83M | 185.27M | 182.85M | 180.80M | 179.04M |
| Diluted average shares | 187.83M | 185.27M | 182.85M | 180.80M | 179.04M |
| EBITDA | 309.69M | 163.32M | 55.43M | 35.34M | 27.52M |
| Net income from continuing op. | 167.65M | 141.56M | -64.08M | 854.03M | -23.85M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 6.84B | 6.38B | 6.00B | 5.85B | 4.69B |
| Current assets | |||||
| Cash | 229.68M | 463.25M | 301.18M | 370.33M | 259.35M |
| Cash equivalents | 525.45M | 261.28M | 286.10M | 278.83M | 178.10M |
| Cash and cash equivalents | 755.13M | 724.53M | 587.28M | 649.16M | 437.45M |
| Other short term investments | 318.68M | 567.01M | 426.60M | 416.23M | 316.36M |
| Accounts receivable | 633.70M | 461.32M | 373.40M | 448.35M | 377.40M |
| Other receivables | — | — | — | — | — |
| Inventory | 1.11B | 894.08M | 776.67M | 698.55M | 680.28M |
| Prepaid assets | — | — | — | — | — |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 141.39M | 104.52M | 110.44M | 129.93M | 130.66M |
| Non current assets | |||||
| Properties | 538.68M | 475.66M | 444.18M | 414.44M | 366.95M |
| Land and improvements | 117.56M | 117.24M | 100.55M | 97.83M | 97.77M |
| Machinery furniture equipment | 257.94M | 260.59M | 244.36M | 229.96M | 206.12M |
| Construction in progress | 100.01M | 143.38M | 136.74M | 109.14M | 111.90M |
| Leases | 58.23M | 59.53M | 55.28M | 55.13M | 51.32M |
| Accumulated depreciation | -867.09M | -802.15M | -720.57M | -635.60M | -549.10M |
| Goodwill | 687.10M | 730.97M | 781.05M | 809.67M | 850.66M |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 294.70M | 338.57M | 388.65M | 417.27M | 456.58M |
| Investments and advances | 611.14M | 333.84M | 507.79M | 285.47M | 411.98M |
| Other non current assets | 1.72B | 1.68B | 1.60B | 1.57B | 671.43M |
| Total liabilities | 1.89B | 1.77B | 1.74B | 1.74B | 1.57B |
| Current liabilities | |||||
| Accounts payable | 315.51M | 231.24M | 199.68M | 191.43M | 240.98M |
| Accrued expenses | 6.19M | 8.29M | 6.04M | 4.49M | 3.44M |
| Short term debt | 502.66M | 10.38M | 10.46M | 11.75M | 372.58M |
| Deferred revenue | 4.62M | 711,000 | 6.96M | 152,000 | 13.04M |
| Tax payable | 2.65M | 16.21M | 1.21M | 19.22M | 11.59M |
| Pensions | 201.07M | 207.57M | 204.45M | 165.02M | 192.47M |
| Other current liabilities | 33.85M | 28.53M | 54.50M | 17.80M | 10.45M |
| Non current liabilities | |||||
| Long term debt | 593.10M | 1.08B | 1.08B | 1.08B | 486.24M |
| Provision for risks and charges | — | — | — | 60.13M | 50.79M |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 119.94M | 100.02M | 113.53M | 174.33M | 98.12M |
| Shareholders equity | |||||
| Common stock | 189,000 | 186,000 | 184,000 | 182,000 | 180,000 |
| Retained earnings | -621.55M | -789.20M | -930.76M | -861.61M | -1.72B |
| Other shareholders equity | -28.79M | -3.87M | 14.43M | -16.14M | 20.16M |
| Total shareholders equity | 4.95B | 4.60B | 4.27B | 4.11B | 3.12B |
| Additional paid in capital | 5.61B | 5.40B | 5.19B | 4.99B | 4.83B |
| Treasury stock | — | — | — | 9.84M | 9.96M |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||
| Net Income | 167.65M | 141.56M | -64.08M | 854.03M | -23.85M | -77.21M | -117.04M | -630.21M | -171.80M | -133.97M | -176.35M | -114.35M | -53.84M | 205.82M | -488,000 | 30.83M | -15.80M | -28.53M | -74.27M | -187.44M | -76.38M | -77.37M | -57.43M | -35.62M | -26.37M | -12.30M |
| Depreciation | 104.39M | 101.97M | 108.04M | 105.17M | 105.30M | 95.67M | 87.86M | 96.91M | 47.19M | 45.87M | 36.01M | 44.34M | 35.05M | 27.74M | 20.98M | 17.62M | 1.09M | 9.79M | 9.75M | 13.28M | 9.44M | 8.50M | 7.00M | 5.73M | 5.42M | 800,000 |
| Deferred Taxes | -44.98M | -52.09M | -15.61M | -889.99M | -82.76M | -68.38M | 44.46M | -228.05M | -76.83M | -25.62M | -8.91M | -9.92M | 4.36M | -230.58M | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 207.10M | 196.31M | 197.26M | 189.71M | 159.87M | 148.82M | 140.26M | 134.64M | 111.53M | 86.41M | 64.38M | 47.34M | 43.91M | 38.36M | 36.01M | 28.34M | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 3.82M | 3.78M | 9.54M | 20.01M | 16.77M | 38.14M | 48.58M | -26.90M | 2.50M | 33.89M | 30.19M | 11.75M | 1.15M | 17.72M | 2.58M | -6.72M | 23.94M | 15.28M | 5.77M | — | 305,000 | 276,000 | — | — | — | -100,000 |
| Accounts Receivable | -190.44M | -82.03M | 65.57M | -59.04M | -37.85M | -54.27M | -25.26M | -51.48M | -16.37M | -25.95M | -8.74M | -4.23M | -18.46M | -13.04M | -19.24M | -37.32M | -2.31M | -8.81M | -1.81M | -1.12M | — | — | -2.19M | -519,000 | -861,000 | -600,000 |
| Accounts Payable | 68.85M | 59.02M | 15.69M | -87.03M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -214.96M | -73.37M | -15.23M | -114.39M | -146.10M | -25.56M | -110.87M | -65.98M | -30.01M | -31.40M | -6.15M | 1.83M | -15.63M | -34.65M | 31.10M | -59.10M | -22.55M | -31.11M | 41.15M | 1.59M | -12.48M | 814,000 | -2.00M | -514,000 | 1.63M | 200,000 |
| Operating Cash Flow | 101.43M | 295.15M | 301.19M | 18.48M | -8.62M | 57.21M | 68.00M | -771.07M | -133.79M | -50.76M | -69.58M | -23.24M | -3.45M | 11.37M | 70.92M | -26.35M | -15.63M | -43.38M | -19.41M | -173.69M | -79.10M | -67.78M | -54.61M | -30.92M | -20.19M | -12.00M |
| Investing Activities | ||||||||||||||||||||||||||
| Capital Expenditures | -96.69M | -120.96M | -95.58M | -114.31M | -145.03M | -144.62M | -199.22M | -148.38M | -227.65M | -117.06M | -65.19M | -44.57M | -73.22M | -49.46M | -89.80M | -56.37M | -22.41M | -24.58M | -6.49M | -24.08M | -5.95M | -4.59M | -17.81M | -3.76M | -22.94M | -6.40M |
| Net Intangibles | -10.92M | -10.58M | -23.65M | -23.21M | -18.38M | — | 125.00M | — | 410.00M | 67.50M | — | — | -81.00M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | -2.79M | -910.15M | — | -9.88M | -1.74M | -1.90M | -36.58M | -17.52M | -1.75M | — | — | — | -14.79M | — | -3.12M | -3.42M | — | -1.50M | — |
| Purchase of Investments | -868.50M | -611.81M | -937.14M | -538.37M | -632.02M | -634.75M | -655.45M | -699.75M | -873.18M | -559.32M | -395.04M | -387.17M | -215.43M | -221.66M | -447.67M | -738.82M | -838.86M | -217.72M | — | -37.44M | -125.08M | -112.07M | -171.87M | -13.70M | -37.60M | -1.10M |
| Sale of Investments | 864.86M | 620.00M | 691.05M | 555.83M | 740.21M | 993.73M | 425.96M | 367.57M | 424.71M | 808.31M | 288.64M | 237.84M | 281.99M | 206.36M | 475.31M | 761.18M | 693.81M | 29.91M | 26.38M | 86.31M | 80.07M | 190.70M | 76.97M | 15.90M | — | — |
| Investing Cash Flow | -100.32M | -9.45M | -342.67M | -30.41M | -12.65M | 264.35M | -430.46M | -484.05M | -1.59B | 128.83M | -298.85M | -195.65M | -8.56M | -101.34M | -97.19M | -19.08M | -151.00M | -192.69M | 54.07M | -29.38M | -50.95M | 70.91M | -137.33M | -1.55M | -68.75M | -8.20M |
| Financing Activities | ||||||||||||||||||||||||||
| Long-Term Debt Issuance | — | — | — | 585.75M | — | — | 481.71M | — | — | — | 726.20M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -2.29M | -2.61M | -3.04M | -381.91M | -5.09M | -374.95M | -26,000 | — | -163,000 | -674,000 | -12.97M | — | -2.78M | -14.28M | -74.79M | -6.59M | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -85.79M | -85.38M | -46.20M | -44.64M | -101.20M | -80.54M | -35.40M | -60.06M | -25.58M | -13.17M | -39.15M | -6.27M | -1.48M | -15.32M | -1.00M | 960,000 | — | 9.35M | — | — | 485,000 | 1.75M | 13.16M | — | — | -100,000 |
| Financing Cash Flow | -88.08M | -87.98M | -49.24M | 109.21M | -106.29M | -455.50M | 446.29M | 652.88M | 862.52M | 103.62M | 673.99M | 229.23M | -4.25M | -29.60M | -75.79M | -5.63M | 15.22M | 149.87M | 7.78M | 1.81M | 95.07M | 3.64M | 147.73M | 6.79M | 70.10M | 19.60M |
| Other Cash Details | ||||||||||||||||||||||||||
| End Cash Position | 755.13M | 724.53M | 587.28M | 649.16M | 437.45M | 493.98M | 598.03M | 408.33M | 397.04M | 875.49M | 568.78M | 180.53M | 46.27M | 88.08M | 167.17M | 222.90M | 228.34M | 89.16M | 38.09M | 13.08M | 121.41M | 33.64M | 12.53M | 16.53M | 23.41M | 9.40M |
| Income Tax Paid | 73.31M | 54.37M | 18.15M | 8.98M | 9.73M | 16.68M | 23.90M | 95.86M | 16.08M | 34.99M | 14.90M | 6.58M | 4.40M | 3.58M | 2.82M | 1.28M | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 10.30M | 10.28M | 10.40M | 12.18M | 8.55M | 11.62M | 8.54M | 8.64M | 9.31M | 9.32M | 2.16M | 6.67M | 7.22M | 10.08M | 9.70M | 10.40M | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 51.65M | 44.36M | 185.31M | -52.15M | -115.14M | -124.41M | -207.98M | -376.22M | -447.15M | -187.48M | -122.53M | -26.96M | -135.80M | -30.72M | -2.07M | -65.54M | -56.91M | -76.75M | -65.64M | -75.12M | -80.77M | -58.46M | -58.66M | -16.49M | -35.88M | -14.50M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Dodge & Cox Stock Fund | Sep 30, 2024 | 8,914,025 | 560.42M | 4.68% |
| Vanguard/Primecap Fund | Sep 30, 2024 | 7,270,808 | 457.12M | 3.82% |
| Growth Fund of America Inc | Nov 30, 2024 | 6,405,939 | 402.74M | 3.36% |
| iShares Core S&P Midcap ETF | Nov 30, 2024 | 6,114,363 | 384.41M | 3.21% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 6,042,949 | 379.92M | 3.17% |
| Vanguard Horizon Fund-Capital Opportunity Fund | Sep 30, 2024 | 5,549,780 | 348.91M | 2.91% |
| Amcap Fund | Nov 30, 2024 | 4,494,821 | 282.59M | 2.36% |
| Vanguard Mid-Cap Index Fund | Sep 30, 2024 | 4,031,296 | 253.45M | 2.12% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 2,848,308 | 179.07M | 1.49% |
| Vanguard Growth Index Fund | Sep 30, 2024 | 2,406,566 | 151.30M | 1.26% |
Article
3 Reasons Growth Investors Will Love BioMarin (BMRN)
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Feb 5, 2025
Article
BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET
SAN RAFAEL, Calif. , Feb. 5, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 19, 2025, at 4:30 p.m.
Feb 5, 2025
Article
4 Stocks That Sport Impressive Interest Coverage Ratio
BMRN, CAKE, LDOS & ENSG's impressive interest coverage ratios highlight that these companies can withstand financial hardships.
Feb 4, 2025
